Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances research identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://robertj491zri0.targetblogs.com/profile